GSK256066 (Trifluoroacetate) (Standard)

GSK256066 (Trifluoroacetate) (Standard) is the analytical standard of GSK256066 (Trifluoroacetate) . This product is intended for research and analytical applications. GSK256066 Trifluoroacetate is a selective and high-affinity phosphodiesterase 4 (PDE) inhibitor, with an IC50 of 3.2 pM for PDE4B. GSK256066 Trifluoroacetate is developed for the research of chronic obstructive pulmonary disease[1].

Product Specifications

CAS Number

[1415560-64-3]

UNSPSC

12352100

Target

Phosphodiesterase (PDE) ; Reference Standards

Related Pathways

Metabolic Enzyme/Protease; Others

Field of Research

Inflammation/Immunology

Smiles

OC(C(F)(F)F)=O.O=C(N)C1=C(C2=CC(S(=O)(C3=CC=CC(C(N(C)C)=O)=C3)=O)=CC(C)=C2N=C1)NC4=CC=CC(OC)=C4

Molecular Formula

C29H27F3N4O7S

Molecular Weight

632.61

References & Citations

[1]Tralau-Stewart CJ, et al. GSK256066, an exceptionally high-affinity and selective inhibitor of phosphodiesterase 4 suitable for administration by inhalation: in vitro, kinetic, and in vivo characterization. J Pharmacol Exp Ther, 2011, 337 (1), 145-154.|[2]Nials AT, et al. In vivo characterization of GSK256066, a high-affinity inhaled phosphodiesterase 4 inhibitor. J Pharmacol Exp Ther, 2011, 337 (1), 137-144.